Content
September 2022, Volume 6, Issue 5
- 647-656 Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
by Lotte Westerink & Jelmer Lennart Jens Nicolai & Maarten Jacobus Postma & Job Frank Martien Boven & Cornelis Boersma - 657-668 Cost-Utility and Budget Impact Analysis of Implementing Anticoagulation Clinics and Point-of-Care Monitoring Devices in Anticoagulated Patients in Argentina
by Osvaldo Ulises Garay & Gonzalo Guiñazú & Yolanda Patricia Adamczuk & Cristina Duboscq - 669-679 Public Preferences and Willingness to Pay for a COVID-19 Vaccine in Iran: A Discrete Choice Experiment
by Alireza Darrudi & Rajabali Daroudi & Masud Yunesian & Ali Akbari Sari - 681-696 Cost-Effectiveness Analysis of a Medial Meniscus Replacement Prosthesis for the Treatment of Patients with Medial Compartment Pain in the United Kingdom
by Mehdi Javanbakht & Atefeh Mashayekhi & Angeline Carlson & Eoin Moloney & Martyn Snow & James Murray & Tim Spalding - 697-710 Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
by Timothy Baker & Helen Johnson & Srividya Kotapati & Andriy Moshyk & Melissa Hamilton & Murat Kurt & Victoria Federico Paly - 711-721 The Physician and Administrator-Reported Cost of Drug Utilization Management to Physician Practices: A Cross-Sectional Survey
by Marie Louise Edwards & Perry T. Yin & Michael Kuehn & Keith Bratti & Noam Kirson & Anupam Jena & Scott Howell - 723-733 Cost-Utility Analysis of Planned Early Delivery or Expectant Management for Late Preterm Pre-eclampsia (PHOENIX)
by Rachael Hunter & Alice Beardmore-Gray & Melanie Greenland & Louise Linsell & Edmund Juszczak & Pollyanna Hardy & Anna Placzek & Andrew Shennan & Neil Marlow & Lucy C. Chappell - 735-743 Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland
by Elisabeth Brock & Giorgio Moschovitis & Micha T. Maeder & Otmar Pfister - 745-756 Cost of Surgical Care at Public Sector District Hospitals in India: Implications for Universal Health Coverage and Publicly Financed Health Insurance Schemes
by Maninder Pal Singh & Shankar Prinja & Kavitha Rajsekar & Praveen Gedam & Vipul Aggarwal & Oshima Sachin & Jyotsna Naik & Ajai Agarwal & Sanjay Kumar & Setu Sinha & Varsha Singh & Prakash Patel & Amit C. Patel & Rajendra Joshi & Avijit Hazra & Raghunath Misra & Divya Mehrotra & Sashi Bhusan Biswal & Ankita Panigrahy & Kusum Lata Gaur & Jai Prakash Pankaj & Dharmesh Kumar Sharma & Kondeti Madhavi & Pulaganti Madhusudana & K. Narayanasamy & A. Chitra & Gajanan D. Velhal & Amit S. Bhondve & Rakesh Bahl & Amit Sachdeva & Sharminder Kaur & Anu Nagar & Balram Bhargava - 757-771 The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland
by Thomas Ward & Tray Brown & Ruth D. Lewis & Melodi Kosaner Kliess & Antonio Ramirez Arellano & Carol M. Quinn
July 2022, Volume 6, Issue 4
- 469-481 Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis
by Zachary Baldwin & Boshen Jiao & Anirban Basu & Joshua Roth & M. A. Bender & Zizi Elsisi & Kate M. Johnson & Emma Cousin & Scott D. Ramsey & Beth Devine - 483-494 Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting
by Sabine Michelsen Raunbak & Anne Sig Sørensen & Louise Hansen & Flemming Skjøth & Torben Bjerregaard Larsen & Lars Holger Ehlers - 495-507 Costs and Effects of Implementing Digital Tomosynthesis in a Population-Based Breast Cancer Screening Program: Predictions Using Results from the To-Be Trial in Norway
by Tron Anders Moger & Åsne Holen & Berit Hanestad & Solveig Hofvind - 509-518 Direct Medical Costs of Four Vaccine-Preventable Infectious Diseases in Older Adults in Spain
by Ángel Gil de Miguel & José María Eiros Bouza & Luis Ignacio Martínez Alcorta & Daniel Callejo & Carlos Miñarro & Laura Amanda Vallejo-Aparicio & Andrea García & Mónica Tafalla & María del Rosario Cambronero & Rubén Rodríguez & Laura Martin-Gomez - 519-537 Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
by Elisabetta Fenu & Vasily Lukyanov & Annabel Acs & Xenia Radu & Stephanie Stypa & Aren Fischer & John K. Marshall & Mark Oppe - 539-548 Differences in Breast Cancer Costs by Cancer Stage and Biomarker Subtype in New Zealand
by Chunhuan Lao & Mohana Mondal & Marion Kuper-Hommel & Ian Campbell & Ross Lawrenson - 549-562 Cost-Effectiveness Analysis of Intravascular Targeted Temperature Management after Cardiac Arrest in England
by Mehdi Javanbakht & Atefeh Mashayekhi & Mohsen Rezaei Hemami & Michael Branagan-Harris & Thomas R Keeble & Mohsen Yaghoubi - 563-574 Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
by Matthew Reaney & Veleka Allen & Amy J. Sehnert & Liang Fang & Albert A. Hagège & Srihari S. Naidu & Iacopo Olivotto - 575-586 Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial
by Matthew Reaney & Prithvi Addepalli & Veleka Allen & John A. Spertus & Chantal Dolan & Amy J. Sehnert & Jennifer T. Fine - 587-594 Cost Analysis of Adjuvant Whole-Brain Radiotherapy Treatment Versus No Whole-Brain Radiotherapy After Stereotactic Radiosurgery and/or Surgery Among Adults with One to Three Melanoma Brain Metastases: Results from a Randomized Trial
by Anh Dam Tran & Angela M. Hong & Mai T. H. Nguyen & Gerald Fogarty & Victoria Steel & Elizabeth Paton & Rachael L. Morton - 595-603 Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms
by Michela Meregaglia & Rosanna Tarricone - 605-617 Economic Evaluation of Using Daily Prednisolone versus Placebo at the Time of an Upper Respiratory Tract Infection for the Management of Children with Steroid-Sensitive Nephrotic Syndrome: A Model-Based Analysis
by Nafsika Afentou & Emma Frew & Samir Mehta & Natalie J. Ives & Rebecca L. Woolley & Elizabeth A. Brettell & Adam R. Khan & David V. Milford & Detlef Bockenhauer & Moin A. Saleem & Angela S. Hall & Ania Koziell & Heather Maxwell & Shivaram Hegde & Eric Finlay & Rodney D. Gilbert & Caroline Jones & Karl McKeever & Wendy Cook & Nicholas J. A. Webb & Martin T. Christian - 619-628 Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis
by Zeki Kocaata & Thomas Wilke & Franz Fischer & Robert Welte & Hermann Einsele - 629-629 Correction to: Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
by Anna-Maria Fontrier & Erica Visintin & Panos Kanavos
May 2022, Volume 6, Issue 3
- 315-328 Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
by Anna-Maria Fontrier & Erica Visintin & Panos Kanavos - 329-342 Community Distribution of Naloxone: A Systematic Review of Economic Evaluations
by Nelda Cherrier & Joanne Kearon & Robin Tetreault & Sophiya Garasia & Emmanuel Guindon - 343-354 Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
by Björn Eliasson & Åsa Ericsson & Adam Fridhammar & Andreas Nilsson & Sofie Persson & Barrie Chubb - 355-365 A Cost-Utility Analysis of Trabecular Bypass Devices Versus Usual Care for Patients With Open-Angle Glaucoma
by Paul R. Healey & Dominic Tilden & Dan Jackson & Lara Aghajanian - 367-376 Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma
by Timothy A. Howell & Louis S. Matza & Monika P. Jun & Jacob Garcia & Annette Powers & David G. Maloney - 377-388 Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis
by Dina Jankovic & Pedro Saramago Goncalves & Lina Gega & David Marshall & Kath Wright & Meena Hafidh & Rachel Churchill & Laura Bojke - 389-403 An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer
by Victory ‘Segun Ezeofor & Llinos Haf Spencer & Simon N. Rogers & Anastasios Kanatas & Derek Lowe & Cherith J. Semple & Jeffrey R. Hanna & Seow Tien Yeo & Rhiannon Tudor Edwards - 405-414 Prevalence and Cost of Care for Parkinson’s Disease in Luxembourg: An Analysis of National Healthcare Insurance Data
by Susanne Schmitz & Michel Vaillant & Christell Renoux & Robert L. Konsbruck & Pierre Hertz & Magali Perquin & Lukas Pavelka & Rejko Krüger & Laetitia Huiart - 415-424 Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
by Vicente Estrada & Miguel Górgolas & José A. Peña & Elena Tortajada & Antonio Castro & María Presa & Itziar Oyagüez - 425-435 Examining the Association between Polish Migrant Status and Health Preferences Using a Novel Application of a Smaller Design EQ-5D-5L Valuation Study
by Dan Kelleher & Samer Kharroubi & Edel Doherty & Gianluca Baio & Ciaran O’Neill - 437-450 Cost-Effectiveness of Constraint-Induced Movement Therapy Implementation in Neurorehabilitation: The ACTIveARM Project
by Lauren J. Christie & Nicola Fearn & Annie McCluskey & Meryl Lovarini & Reem Rendell & Alison Pearce - 451-460 Cost Savings of Mother’s Own Milk for Very Low Birth Weight Infants in the Neonatal Intensive Care Unit
by Tricia J. Johnson & Aloka L. Patel & Michael E. Schoeny & Paula P. Meier - 461-468 Stage-Related Cost of Treatment of Bladder Cancer in Brazil
by Fernando Korkes & Frederico Timóteo & Luiza C. B. Soledade & Lara S. Bugalho & Guilherme A. Peixoto & Vanessa D. Teich & Sidney Glina
March 2022, Volume 6, Issue 2
- 137-145 Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan
by Imad Treish & Abeer Al Rabayah & Saad Jaddoua & Haitham Tuffaha - 147-167 Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review
by Ana-Catarina Pinho-Gomes & John Cairns - 169-178 Budget Impact of the Vest™ High Frequency Chest Wall Oscillation System for Managing Airway Clearance in Patients with Complex Neurological Disorders: A US Healthcare Payers’ Perspective Analysis
by Amir Ansaripour & Kari Roehrich & Atefeh Mashayekhi & Mwanamisi Wanjala & Shani Noel & Mohsen Rezaei Hemami & Angela Murray & Mehdi Javanbakht - 179-192 Cost Effectiveness of Internet-Delivered Acceptance and Commitment Therapy for Patients with Severe Health Anxiety: A Randomised Controlled Trial
by Bettina Wulff Risør & Ditte Hoffmann Frydendal & Marie Konge Villemoes & Camilla Palmhøj Nielsen & Charlotte Ulrikka Rask & Lisbeth Frostholm - 193-210 Examining Ways to Improve Weight Control Programs’ Population Reach and Representativeness: A Discrete Choice Experiment of Financial Incentives
by Wen You & Yuan Yuan & Kevin J. Boyle & Tzeyu L. Michaud & Chris Parmeter & Richard W. Seidel & Paul A. Estabrooks - 211-218 Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study
by Pedro Labisa & Valeska Andreozzi & Melina Mota & Susana Monteiro & Rita Alves & João Almeida & Björn Vandewalle & Jorge Felix & Katharina Buesch & Hugo Canhão & Igor Beitia Ortiz de Zarate - 219-229 Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016–2018
by Rose J. Geurten & Jeroen N. Struijs & Arianne M. J. Elissen & Henk J. G. Bilo & Chantal Tilburg & Dirk Ruwaard - 231-239 Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States
by Siu Hing Lo & Andrew Lloyd & Shuayb Elkhalifa & Zlatko Sisic & Floortje E. Nooten - 241-252 Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective
by Will Dunlop & Marjolijn Keep & Peter Elroy & Ignacio Diaz Perez & Mario J. N. M. Ouwens & Tina Sarbajna & Yiduo Zhang & Alastair Greystoke - 253-263 Budget Impact Analysis of an Epigenetic Test Used for Diagnosing Fetal Alcohol Spectrum Disorder from the Perspective of a Laboratory Budget Holder in Manitoba, Canada
by Patrick Berrigan & Geoffrey G. Hicks & Wendy J. Ungar & Jennifer D. Zwicker - 265-275 The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation
by Ahmed H. Seddik & Nima Melzer & Foteini Tsotra & Dennis A. Ostwald - 277-291 Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
by Ahmed Alghamdi & Bander Balkhi & Abdulaziz Altowaijri & Nasser Al-shehri & Lewis Ralph & Emily-Ruth Marriott & Michael Urbich & Fawaz Aljanad & Rima Aziziyeh - 293-302 Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium
by B. Gillain & G. Degraeve & T. Dreesen & G. De Bruecker & E. Buntinx & D. Beke & C. Kestens & E. Valassopoulou & F. Verhelst & E. Peeters & S. Pype & C. De Vos & D. Strens & I. Vandersmissen - 303-313 Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
by Dikshyanta Rana & Claudia Geue & Kelly Baillie & Jiafeng Pan & Tanja Mueller & Jennifer Laskey & Marion Bennie & Julie Clarke & Robert J. Jones & Ailsa Brown & Olivia Wu
January 2022, Volume 6, Issue 1
- 5-8 NICE and the EQ-5D-5L: Ten Years Trouble
by Chris Sampson - 9-19 A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment
by Sydney C. Yuen & Adaeze Q. Amaefule & Hannah H. Kim & Breanna-Verissa Owoo & Emily F. Gorman & T. Joseph Mattingly - 21-32 The Utility of Economic Measures to Quantify the Burden of Tinnitus in Affected Individuals: A Scoping Review
by Elza Daoud & Charlotte Caimino & Michael A. Akeroyd & Arnaud J. Noreña & David M. Baguley - 33-45 Cost-Effectiveness Analysis of the Treatment Strategies with or without Opioid Medications in Surgery-Eligible Patients with Osteoarthritis in Japan
by Tomoyuki Takura & Akira Yuasa & Naohiro Yonemoto & Sven Demiya & Hiroyuki Matsuda & Nozomi Ebata & Koichi Fujii & Muneaki Ishijima - 47-62 Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden
by I. Oostrum & T. A. Russell-Smith & M. Jakobsson & J. Torup Østby & B. Heeg - 63-72 A Real-World Assessment of Outcomes, Health Resource Utilization, and Costs Associated with Cerebral Edema in US Patients with Large Hemispheric Infarction
by Nicole Tsao & Qiang Hou & Shih-Yin Chen & Steven R. Messe - 73-83 Continuous Monitoring of Respiratory Rate with Wearable Sensor in Patients Admitted to Hospital with Pneumonia Compared with Intermittent Nurse-Led Monitoring in the United Kingdom: A Cost-Utility Analysis
by Mehdi Javanbakht & Maziar Moradi-Lakeh & Atefeh Mashayekhi & Jowan Atkinson - 85-94 Cost Effectiveness of a Cultural Physical Activity Intervention to Reduce Blood Pressure Among Native Hawaiians with Hypertension
by Ashley F. Railey & Clemma Muller & Carolyn Noonan & Maureen Schmitter-Edgecombe & Ka’imi Sinclair & Corin Kim & Mele Look & J. Keawe‘aimoku Kaholokula - 95-104 Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
by Massimiliano Bonifacio & Vikalp Maheshwari & Diana Tran & Gianluca Agostoni & Kalitsa Filioussi & Ricardo Viana - 105-121 Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex
by Siu Hing Lo & Jade Marshall & Hanna Skrobanski & Andrew Lloyd - 123-135 Economic Analysis of the CADScor System for Ruling Out Coronary Artery Disease in England
by Mehdi Javanbakht & Atefeh Mashayekhi & Mohsen Rezaei Hemami & Michael Branagan-Harris & Eoin Moloney
December 2021, Volume 5, Issue 4
- 561-576 Evidence-Based Medicine and Healthcare Quality in the Context of Information Failure: The Case of the UK Fertility Sector
by Minyan Zhu - 577-586 gammaCore for Cluster Headaches: A NICE Medical Technologies Guidance
by Susan O’Connell & Megan Dale & Helen Morgan & Kimberley Carter & Rhys Morris & Grace Carolan-Rees - 587-603 Inclusion of Additional Unintended Consequences in Economic Evaluation: A Systematic Review of Immunization and Tuberculosis Cost-Effectiveness Analyses
by Liv Solvår Nymark & Alex Miller & Anna Vassall - 605-612 Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review
by Tamás Zelei & Nicholas D. Mendola & Baher Elezbawy & Bertalan Németh & Jonathan D. Campbell - 613-623 Hospital Costs of Extracorporeal Membrane Oxygenation in Adults: A Systematic Review
by Annemieke Oude Lansink-Hartgring & Olivier van Minnen & Karin M. Vermeulen & Walter M. van den Bergh - 625-633 Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States
by Ash Bullement & Emma S. Knowles & Pronabesh DasMahapatra & Talaha Ali & Ron Preblick - 635-647 A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile
by Manuel Antonio Espinoza & Rubén Rojas & Alessandro Zaupa & Carlos Balmaceda - 649-653 Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan
by Robin L. Corelli & Thanh G. Tu & Kyoung J. Lee & Drake Dinh & Kristin R. Gericke & Karen Suchanek Hudmon - 655-664 Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
by Yared Belete Belay & Eskinder Eshetu Ali & Karen Y. Chung & Gebremedhin Beedemariam Gebretekle & Beate Sander - 665-675 Impact of Including Carer Information in Time Trade-Off Tasks: Results from a Pilot Study
by David J. Mott & Iain Leslie & Koonal Shah & Jennifer Rowell & Nicolas Scheuer - 677-691 Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK
by T. Alexander Russell-Smith & James Brockbank & Carla Mamolo & Christopher Knight - 693-700 Cost-Effectiveness of Peer-Educator–Delivered Lifestyle Modification for Type 2 Diabetes Prevention in a Young Healthy Population in Sri Lanka: A Trial-Based Economic Evaluation and Economic Model
by James Shearer & Miral Kalyani & Anastasios Mangelis & Dileep Silva & Padmal Silva & Mahen Wijesuriya & Janaka Karalliedde - 701-713 Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making
by Jason Gordon & Angela Stainthorpe & Beverley Jones & Ian Jacob & Nadine Hertel & Jose Diaz & Yong Yuan & John Borrill - 715-725 Estimation of Health-Related Utilities for 177Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities
by Ioana-Alexandra Soare & Oscar Leeuwenkamp & Louise Longworth - 727-736 The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US
by Satabdi Chatterjee & David Walker & Tomomi Kimura & Rajender R. Aparasu - 737-753 Economic Evaluation of Transperineal versus Transrectal Devices for Local Anaesthetic Prostate Biopsies
by Edward C. F. Wilson & Alice Wreford & Priya Tamer & Kelly Leonard & Hannah Brechka & Vincent J. Gnanapragasam - 755-764 Direct and Indirect Costs of Non-surgical Treatment for Acute Tonsillitis in Children in Southeast Nigeria
by Maduka Donatus Ughasoro & James Onuorah Akpeh & Nneamaka Echendu & Somkene Okpala & Nneka Getrude Mgbachi & Ogochukwu Chinelo Okanya & Obinna Emmanuel Onwujekwe - 765-778 Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective
by Nan Qiao & Ralph Insinga & Thomas Burke & Gilberto Lopes
September 2021, Volume 5, Issue 3
- 339-348 Revision of Ireland’s Cost-Effectiveness Threshold: New State-Industry Drug Pricing Deal Should Adequately Reflect Opportunity Costs
by James F. O’Mahony - 349-364 National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison
by Deepshikha Sharma & Arun Kumar Aggarwal & Laura E. Downey & Shankar Prinja - 365-383 A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
by Nan Qiao & Ralph Insinga & Gilberto de Lima Lopes Junior & John Cook & Martin Sénécal - 385-396 High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?
by Wolfgang Greiner & Keyur Patel & Christina-Jane Crossman-Barnes & Troels Vingtoft Rye-Andersen & Christian Hvid & Tom Vandebrouck - 397-410 Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology
by Graeme Ball & Mitch Levine & Lehana Thabane & Jean-Eric Tarride - 411-423 State-Level Variations and Factors Associated with Adult Vaccination Coverage: A Multilevel Modeling Approach
by Diana Garbinsky & Shannon Hunter & Elizabeth M. La & Sara Poston & Cosmina Hogea - 425-435 The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease
by Dat T. Tran & Dan Palfrey & Robert Welsh - 437-447 Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan
by Kensuke Moriwaki & Saki Uechi & Takaaki Fujiwara & Yu Hagino & Kojiro Shimozuma - 449-458 Economic Impact of Coverage Expansion for Non-invasive Prenatal Testing Through a Performance-Based Risk-Sharing Agreement
by Taryn A. G. Quinlan & Brock Schroeder & Sue Kwon & Jane F. Barlow & Michael S. Sherman & Heather D. Anderson & Garth Wright & R. Brett McQueen - 459-467 Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis
by Hansoo Kim & Greg Cook & Stephen Goodall & Danny Liew - 469-473 Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial
by Yoav Golan & Yuexin Tang & Shahrul Mt-Isa & Hong Wan & Valerie Teal & Cyrus Badshah & Sanjeet Dadwal - 475-489 Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective
by Deirdre B. Blissett & Joerg S. Steier & Yakubu G. Karagama & Rob S. Blissett - 491-504 Cost-effectiveness of a Province-wide Quality Improvement Initiative for Reducing Potentially Inappropriate Use of Antipsychotics in Long-Term Care in British Columbia, Canada
by Asif Raza Khowaja & Christina Krause & Colleen Kennedy & Ben Ridout & Sarah Carriere & Craig Mitton - 505-518 Psychometric Validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM)
by Meryl Brod & Michael Højby Rasmussen & Knud Vad & Suzanne Alolga & Donald M. Bushnell & Jacques Bedoin & Aristides Maniatis - 519-531 Economic Analysis of Transforaminal Lumbar Interbody Fusion Surgery Utilizing a Curved Bone Removal Device
by John H. Peloza & Michael A. Millgram & Erel Jacobian & Daniel E. Kolsky & Richard D. Guyer & Jean-Charles Le Huec & Ely Ashkenazi - 533-544 Short-Term Excess Healthcare Costs Associated with Cardiovascular Events Among Adults with Type 2 Diabetes in Israel: A Retrospective Cohort Study
by Cheli Melzer Cohen & Nino Hallén & Gabriel Chodick & Lotmit Bourvine & Tal Waner & Avraham Karasik - 545-557 Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications
by Charles Ebuka Okafor - 559-559 Correction to: Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications
by Charles Ebuka Okafor
June 2021, Volume 5, Issue 2
- 139-141 Value of Information Analysis: Are We There Yet?
by Haitham Tuffaha - 143-155 Mixture Cure Models in Oncology: A Tutorial and Practical Guidance
by Federico Felizzi & Noman Paracha & Johannes Pöhlmann & Joshua Ray - 157-173 Health Economic Evidence of Point-of-Care Testing: A Systematic Review
by Deon Lingervelder & Hendrik Koffijberg & Ron Kusters & Maarten J. IJzerman - 175-186 Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma
by Neerav Monga & Jamie Garside & Matthew S. Davids & Constantine Tam & Katherine Ward & Iain Fotheringham & Peter O’Donovan & Lori Parisi & Christoph Tapprich - 187-195 Can Private Provision of Primary Care Contribute to the Spread of Antibiotic Resistance? A Study of Antibiotic Prescription in Sweden
by David Granlund & Yana V. Zykova - 197-209 Minimally Invasive Sacroiliac Joint Fusion with Triangular Titanium Implants: Cost-Utility Analysis from NHS Perspective
by Deirdre B. Blissett & Rob S. Blissett & Matthew P. Newton Ede & Philip M. Stott & Daniel J. Cher & W. Carlton Reckling - 211-219 Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France
by Bruno Detournay & Zahra Boultif & Amar Bahloul & Viviane Jeanbat & Julien Robert - 221-236 The Cost Effectiveness of Mental Health Treatment in the Lifetime of Older Adults with HIV in New York City: A Markov Approach
by Juan J. DelaCruz & Mark Brennan-Ing & Andreas Kakolyris & Omar Martinez - 237-244 An Exploration on Attribute Non-attendance Using Discrete Choice Experiment Data from the Irish EQ-5D-5L National Valuation Study
by Edel Doherty & Anna Hobbins & David G. T. Whitehurst & Ciaran O’Neill - 245-250 Exploring Patient-Reported Costs Related to Hepatitis C on the Medical Crowdfunding Page GoFundMe®
by T. Joseph Mattingly & Karen Li & Arnold Ng & Tieu-Long Ton-Nu & Jennifer Owens - 251-260 Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
by Ben Rothwell & Christopher Kiff & Caroline Ling & Thor-Henrik Brodtkorb - 261-273 Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market
by Sreenivasa Murthy & Pankaj Aneja & Arthur Joseph Asirvatham & Lise Lotte N. Husemoen & Nicolai A. Rhee & Jothydev Kesavadev - 275-284 Attributable Cost of Adult Hospitalized Pneumonia Beyond the Acute Phase
by Derek Weycker & Aaron Moynahan & Amanda Silvia & Reiko Sato - 285-298 Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?
by Giancarlo Pruneri & Filippo Braud & Anna Sapino & Massimo Aglietta & Andrea Vecchione & Raffaele Giusti & Caterina Marchiò & Stefania Scarpino & Anna Baggi & Giuseppe Bonetti & Jean Marie Franzini & Marco Volpe & Claudio Jommi - 299-310 Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
by Kristine Kreis & Dirk Horenkamp-Sonntag & Udo Schneider & Jan Zeidler & Gerd Glaeske & Lothar Weissbach - 311-318 The Actual Operative Costs of Liver Transplantation and Normothermic Machine Perfusion in a Canadian Setting
by Alexandria N. Webb & Dayne L. Izquierdo & Dean T. Eurich & A. M. James Shapiro & David L. Bigam - 319-329 Disparities in the Wage-and-Salary Earnings, Determinants, and Distribution of Health Economics, Outcomes Research, and Market Access Professionals: An Exploratory Study
by Ioana Popovici & Manuel J. Carvajal & Patti Peeples & Silvia E. Rabionet - 331-337 Cost of Revision Total Knee Replacement: A Protocol for Systematic Review and Meta-Analysis
by Charles Ebuka Okafor & Son Nghiem & Christopher Vertullo & Joshua Byrnes
March 2021, Volume 5, Issue 1
- 1-2 Want to Improve Public Health Access? Let’s Start with the Basics: Measuring Efficiency Correctly
by Antony Andrews - 3-11 Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions
by Melissa H. Roberts & Gary T. Ferguson - 13-22 Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rachel Houten & Janette Greenhalgh & James Mahon & Sarah Nevitt & Sophie Beale & Angela Boland & Tosin Lambe & Yenal Dundar & Eleanor Kotas & Joanne McEntee - 23-34 Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis
by Machaon Bonafede & Rina Mehta & Gilwan Kim & Ila Sruti & Marc Tian & Corey Pelletier & Neil Goldfarb - 35-44 Economic Burden of Chronic Obstructive Pulmonary Disease Patients in Malaysia: A Longitudinal Study
by Anees ur Rehman & Mohamed Azmi Ahmad Hassali & Sohail Ayaz Muhammad & Sadia Shakeel & Ong Siew Chin & Irfhan Ali Bin Hyder Ali & Jaya Muneswarao & Rabia Hussain - 45-55 Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder
by Greta Lozano-Ortega & Carol R. Schermer & David R. Walker & Shelagh M. Szabo & Basia Rogula & Alison M. Deighton & Katherine L. Gooch & Noll L. Campbell - 57-69 Investigation of Factors Considered by Health Technology Assessment Agencies in Eight Countries
by Akira Yuasa & Naohiro Yonemoto & Sven Demiya & Chihiro Foellscher & Shunya Ikeda - 71-76 Costs of Respiratory Syncytial Virus Hospitalizations in Colombia
by Jefferson Antonio Buendía & Diana Guerrero Patiño - 77-88 The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development
by Adam Fridhammar & Ulrika Axelsson & Ulf Persson & Anders Bjartell & Carl A. K. Borrebaeck - 89-100 Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States
by Mohamed I. Elsaid & You Li & Carolyn Catalano & Carlos D. Minacapelli & Kapil Gupta & Vinod K. Rustgi - 101-109 Do Rural Residents in China Understand EQ-5D-5L as Intended? Evidence From a Qualitative Study
by Fan Yang & Shan Jiang & Xiao-ning He & Hong-chao Li & Hong-yan Wu & Tian-tian Zhang & Jing Wu - 111-120 Costs and Extra Length of Stay because of Neonatal Bloodstream Infection at a Teaching Hospital in Ghana
by Ama Pokuaa Fenny & Evans Otieku & Kwaku Appiah-Korang Labi & Felix Ankomah Asante & Ulrika Enemark - 121-127 Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014
by Christine M. Cramer-van der Welle & Bas J. M. Peters & Maarten J. Deenen & Franz M. N. H. Schramel & Ewoudt M. W. Garde - 129-131 Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value
by Michaela R. Anderson & Peter B. Bach & Matthew R. Baldwin - 133-137 Gaining Patient Input on Naming a Novel Patient-Reported Outcome Instrument in Chronic Weight Management
by Heather Rozjabek & John Fastenau & Samara Bennett & Lydia Min-Joo Lee
December 2020, Volume 4, Issue 4
- 557-561 How Should a Safe and Effective COVID-19 Vaccine be Allocated? Health Economists Need to be Ready to Take the Baton
by Laurence S. J. Roope & John Buckell & Frauke Becker & Paolo Candio & Mara Violato & Jody L. Sindelar & Adrian Barnett & Raymond Duch & Philip M. Clarke - 563-574 Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Angela Stainthorpe & Nigel Fleeman & Rachel Houten & Marty Chaplin & Angela Boland & Sophie Beale & Yenal Dundar & Joanne McEntee & Isabel Syndikus - 575-591 Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews
by Neerav Monga & Jamie Garside & Binu Gurung & Joan Quigley & Peter O’Donovan & Christoph Tapprich & Loretta Nastoupil & Catherine Thieblemont & Christina Loefgren - 593-603 Economic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in France
by Olivier Heinzlef & Guillaume Molinier & Benoît Hille & Lise Radoszycki & Paul Dourgnon & Juliette Longin - 605-613 Cost Analysis of the Automated Examination of Urine with the Sysmex UN-Series™ in a Spanish Population
by Óscar Herráez Carrera & María Del Monte Jarabo Bueno - 615-624 A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study
by Fernando de Andrés-Nogales & Miguel Ángel Casado & José Luis Trillo & José María Ruiz-Moreno & José Manuel Martínez-Sesmero & Gemma Peralta & José Luis Poveda & Pere Ortiz & Emilio Ignacio & Javier Zarranz-Ventura & Patricia Udaondo & Carlos Mur & Eloísa Álvarez & Enrique Cervera & Mercedes Martínez & Iñaki Llorente & Jacinto Zulueta & Mariano Rodríguez-Maqueda & Alfredo García-Layana & José Martínez-Olmos - 625-633 Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis
by Shouki Bazarbashi & Edward B. De Vol & Fatma Maraiki & Ahmed Al-Jedai & Afshan A. Ali & Ali M. Alhammad & Ibrahim A. Aljuffali & Michael Iskedjian - 635-648 Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
by Bernd Schweikert & Chiara Malmberg & Örjan Åkerborg & Gayathri Kumar & Debby Nott & Sandeep Kiri & Christophe Sapin & Susanne Hartz - 649-655 Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy Trials
by Katherine Dick & Andrew Briggs & Henrik Brandi - 657-667 Observational Cost-Effectiveness Analysis Using Routine Data: Admission and Discharge Care Bundles for Patients with Chronic Obstructive Pulmonary Disease
by Padraig Dixon & William Hollingworth & Jonathan Benger & James Calvert & Melanie Chalder & Anna King & Stephanie MacNeill & Katherine Morton & Emily Sanderson & Sarah Purdy - 669-677 The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis
by Justin Carrico & Yang Zhao & Xiaoying Jia & Thor-Henrik Brodtkorb & Alan Mendelsohn & Simon Lowry - 679-686 A Corticosteroid-Eluting Sinus Implant Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis: A UK-Based Cost-Effectiveness Analysis
by Mehdi Javanbakht & Hesham Saleh & Mohsen Rezaei Hemami & Michael Branagan-Harris & Margaret Boiano - 687-696 Estimation of the Incremental Cumulative Cost of HIV Compared with a Non-HIV Population
by Joshua P. Cohen & Anne Beaubrun & Yao Ding & Rolin L. Wade & Dionne M. Hines - 697-710 Is Protocolised Weaning that Includes Early Extubation Onto Non-Invasive Ventilation More Cost Effective Than Protocolised Weaning Without Non-Invasive Ventilation? Findings from the Breathe Study
by Iftekhar Khan & Mandy Maredza & Melina Dritsaki & Dipesh Mistry & Ranjit Lall & Sarah E. Lamb & Keith Couper & Simon Gates & Gavin D. Perkins & Stavros Petrou
September 2020, Volume 4, Issue 3
- 393-395 The Cost Effectiveness of Stockpiling Drugs, Vaccines and Other Health Resources for Pandemic Preparedness
by Pedro Plans-Rubió - 397-401 Economic Evaluations of Pharmacological Treatments in Heart Failure Patients: A Methodological Review with a Focus on Key Model Drivers
by Gian Luca Di Tanna & Shuxian Chen & Anna Bychenkova & Heidi S. Wirtz & Karen L. Burrows & Gary Globe - 403-418 Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review
by Peter Wigfield & Urbano Sbarigia & Mahmoud Hashim & Talitha Vincken & Bart Heeg - 419-425 Benefit–Cost Analysis of the Danish Sun Safety Campaign 2007–2015: Cost Savings from Sunburn and Sunbed Use Reduction and Derived Skin Cancer Reductions 2007–2040 in the Danish Population
by Brian Køster & Maria K. H. Meyer & Jes Søgaard & Peter Dalum - 427-438 Cost-Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT
by William Hollingworth & Christopher G. Fawsitt & Padraig Dixon & Larisa Duffy & Ricardo Araya & Tim J. Peters & Howard Thom & Nicky J. Welton & Nicola Wiles & Glyn Lewis - 439-447 A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use
by Sreevalsa Appukkuttan & Krishna Tangirala & Svetlana Babajanyan & Lonnie Wen & Stacey Simmons & Neal Shore - 449-458 Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
by C. Rinciog & A. Diamantopoulos & A. Gentilini & B. Bondue & C. Dahlqvist & A. Froidure & W. A. Wuyts & S. Soulard - 459-472 DyeVert™ PLUS EZ System for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Diagnostic Coronary Angiography and/or Percutaneous Coronary Intervention: A UK-Based Cost–Utility Analysis
by Mehdi Javanbakht & Mohsen Rezaei Hemami & Atefeh Mashayekhi & Michael Branagan-Harris & Azfar Zaman & Yahya Al-Najjar & Donal O’Donoghue & Farzin Fath-Ordoubadi & Stephen Wheatcroft - 473-483 Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
by Robert M. Rifkin & Jill A. Bell & Pronabesh DasMahapatra & Michael Hoole & Maria Lowe & Chris Curran & Scott Campbell & Peijie Hou & Dorothy Romanus - 485-497 Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
by Itziar Oyagüez & Carmen Suárez & José Luis López-Sendón & José Ramón González-Juanatey & Fernando Andrés-Nogales & Jorge Suárez & Carlos Polanco & Javier Soto - 499-510 Cost Effectiveness of Antenatal Lifestyle Interventions for Preventing Gestational Diabetes and Hypertensive Disease in Pregnancy
by Cate Bailey & Helen Skouteris & Cheryce L. Harrison & Jacqueline Boyle & Rebeccah Bartlett & Briony Hill & Shakila Thangaratinam & Helena Teede & Zanfina Ademi - 511-517 Self-Monitoring and Management of Blood Pressure in Patients with Stroke or TIA: An Economic Evaluation of TEST-BP, A Randomised Controlled Trial
by Lois G. Kim & Edward C. F. Wilson & William J. Davison & Allan B. Clark & Phyo K. Myint & John F. Potter - 519-528 Burden of Cardiovascular Disease in Adult Patients with Type 1 Diabetes in the US
by Steve Edelman & Fang Liz Zhou & Ronald Preblick & Sumit Verma & Sachin Paranjape & Michael J. Davies & Vijay N. Joish - 529-539 HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?
by Mikyung Kelly Seo & Oddbjørn Straume & Lars A. Akslen & John Cairns - 541-547 Metabolic Acidosis in Preterm Infants is Associated with a Longer Length of Stay in the Neonatal Intensive Care Unit
by Marika Paul & Jamie Partridge & Bridget Barrett-Reis & Kaashif A. Ahmad & Pattabhi Machiraju & Hemalatha Jayapalan & Richard J. Schanler - 549-550 Comment on: “Systematic Review of Economic Evaluations in Primary Open-Angle Glaucoma: Decision Analytic Modeling Insights”
by Omar Salamanca - 551-552 Authors’ Reply to Salamanca: “Systematic Review of Economic Evaluations in Primary Open Angle Glaucoma: Decision Analytic Modeling Insights”
by Jose Bartelt-Hofer & Steffen Flessa - 553-554 Correction to: Benefit–Cost Analysis of the Danish Sun Safety Campaign 2007–2015: Cost Savings from Sunburn and Sunbed Use Reduction and Derived Skin Cancer Reductions 2007–2040 in the Danish Population
by Brian Køster & Maria K. H. Meyer & Jes Søgaard & Peter Dalum
June 2020, Volume 4, Issue 2
- 203-205 Learnings for Health Economics from the Early Stages of the COVID-19 Pandemic
by Anthony J. Hatswell - 207-210 Group Testing for SARS-CoV-2: Forward to the Past?
by Koen B. Pouwels & Laurence S. J. Roope & Adrian Barnett & David J. Hunter & Terry M. Nolan & Philip M. Clarke - 211-222 A Systematic Review of Model-Based Economic Evaluations of Treatments for Venous Leg Ulcers
by Ashley Layer & Emma McManus & N. J. Levell - 223-233 Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review
by T. I. Armina Padmasawitri & Sarah Maria Saragih & Gerardus W. Frederix & Olaf Klungel & Anke M. Hövels - 235-247 Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
by Herbert H. Loong & Carlos K. H. Wong & Linda Kam Suet Leung & Praveen Dhankhar & Ralph P. Insinga & Sheenu Chandwani & Danny C. Hsu & Mary Y. K. Lee & Min Huang & James Pellissier & Akanksha Rai & Monika Achra & Seng Chuen Tan - 249-261 Cost of Delivering Secondary Healthcare Through the Public Sector in India
by Shankar Prinja & Akashdeep Singh Chauhan & Pankaj Bahuguna & Sakhtivel Selvaraj & V. R. Muraleedharan & Thiagarajan Sundararaman - 263-276 Touch for Health: Use of Pavlovian Processes with Physical Touch as a Means to Improve Menstrual Hygiene Management Initiatives, Measured by Willingness to Pay
by Siobhan K. Yilmaz & Alok K. Bohara & Soumi Roy Chowdhury - 277-286 Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
by Margarita Capel & Andreea Ciudin & María Mareque & Raquel María Rodríguez-Rincón & Susana Simón & Itziar Oyagüez - 287-296 Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines
by Emma Connolly & Helen O’Donnell & Felicity Lamrock & Lesley Tilson & Michael Barry - 297-305 Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts
by D. Coyle & Pierre J. A. Villeneuve - 307-319 Ticagrelor Removal by CytoSorb® in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis
by Mehdi Javanbakht & Miranda Trevor & Mohsen Rezaei Hemami & Kazem Rahimi & Michael Branagan-Harris & Fabian Degener & Daniel Adam & Franziska Preissing & Jörg Scheier & Suzanne F. Cook & Eric Mortensen - 321-330 Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands
by Judith J. Gout-Zwart & Lisa A. Jong & Lisanne Saptenno & Maarten J. Postma - 331-342 Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India
by Suhaj Abdulsalim & Mazhuvancherry Kesavan Unnikrishnan & Mohan K. Manu & Saud Alsahali & Alian A. Alrasheedy & Antony P. Martin & Brian Godman & Abubakr A. Alfadl - 343-351 Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection
by Rachael Batteson & Rose Hart & Matthew Hemstock & Kyna Gooden & Srividya Kotapati & Stephane Roze & Dawn Lee & Adenike Amadi - 353-359 The Costs of Industry-Sponsored Drug Trials in Canada
by Dat T. Tran & Ilke Akpinar & Philip Jacobs - 361-380 A Nationwide Study of Prevalence Rates and Characteristics of 199 Chronic Conditions in Denmark
by Michael Falk Hvidberg & Soeren Paaske Johnsen & Michael Davidsen & Lars Ehlers - 381-388 Treatment Patterns and Costs Associated with Stage IV Non-Small Cell Lung Cancer in a Mexican Population: A Chart Review
by Jorge Arturo Alatorre & Saúl Campos-Gómez & Emmanuel De la Mora & Diego Novick & Angélica Cruz & Jimena María Iglesias-Chiesa - 389-392 Out-of-Pocket Cancer Care Costs and Value Frameworks: A Case Study in a Community Oncology Practice with a Financial Navigator Program
by Christine Leopold & Carina Araujo-Lane & Carol Rosenberg & Melissa Gilkey & Anita K. Wagner
March 2020, Volume 4, Issue 1
- 1-4 Registered Reports: Time to Radically Rethink Peer Review in Health Economics
by Philip Clarke & John Buckell & Adrian Barnett - 5-12 Systematic Review of Economic Evaluations in Primary Open-Angle Glaucoma: Decision Analytic Modeling Insights
by Jose Bartelt-Hofer & Lilia Ben-Debba & Steffen Flessa - 13-25 Health State Utility Data in Cystic Fibrosis: A Systematic Review
by Bishal Mohindru & David Turner & Tracey Sach & Diana Bilton & Siobhan Carr & Olga Archangelidi & Arjun Bhadhuri & Jennifer A. Whitty - 27-36 The Health System Costs of Potentially Inappropriate Prescribing: A Population-Based, Retrospective Cohort Study Using Linked Health Administrative Databases in Ontario, Canada
by Cody D. Black & Kednapa Thavorn & Doug Coyle & Lise M. Bjerre - 37-44 The Use of Computer Simulation Modeling to Estimate Complications in Patients with Type 2 Diabetes Mellitus: Comparative Validation of the Cornerstone Diabetes Simulation Model
by Zhuo T. Su & Jose Bartelt-Hofer & Stephen Brown & Elisheva Lew & Luc Sauriol & Lieven Annemans & Daniel T. Grima - 45-60 Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa
by S. Boyer & M. L. Nishimwe & L. Sagaon-Teyssier & L. March & S. Koulla-Shiro & M.-Q. Bousmah & R. Toby & M. P. Mpoudi-Etame & N. F. Ngom Gueye & A. Sawadogo & C. Kouanfack & L. Ciaffi & B. Spire & E. Delaporte - 61-69 An Evaluation of Diagnosis-Related Group (DRG) Implementation Focused on Cancer DRGs in Greek Public Hospitals
by Panos Panagiotopoulos & Nikos Maniadakis & George Papatheodoridis & Dimitris Pektasidis - 71-77 Return on Investment of Free Colorectal Cancer Screening Tests in a Primarily Rural Uninsured or Underinsured Population in Northeast Texas
by Gabriela Orsak & Anastasia Miller & Carlton M. Allen & Karan P. Singh & Paul McGaha - 79-90 Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
by Hélène Parise & Robert Espinosa & Katherine Dea & Pablo Anaya & Giovanny Montoya & Daniel Bin Ng - 91-103 Healthcare, Sickness Absence, and Disability Pension Cost Trajectories in the First 5 Years After Diagnosis with Multiple Sclerosis: A Prospective Register-Based Cohort Study in Sweden
by Korinna Karampampa & Hanna Gyllensten & Fei Yang & Chantelle Murley & Emilie Friberg & Jan Hillert & Kristina Alexanderson - 105-117 Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis
by Natalie Boytsov & Xiang Zhang & Kristin A. Evans & Barbara H. Johnson - 119-131 US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study
by Dominic Pilon & Holly Szukis & Kruti Joshi & David Singer & John J. Sheehan & Jennifer W. Wu & Patrick Lefebvre & Paul Greenberg - 133-142 Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data
by Ash Bullement & Samuel Thomas McMordie & Anthony James Hatswell & Nanxin Li & Koo Wilson - 143-157 Early Economic Evaluation to Identify the Necessary Test Characteristics of a New Typhoid Test to be Cost Effective in Ghana
by Samuel N. Frempong & Andrew J. Sutton & Clare Davenport & Pelham Barton - 159-169 A Cost-Effectiveness Analysis Comparing the VivaSight Double-Lumen Tube and a Conventional Double-Lumen Tube in Adult Patients Undergoing Thoracic Surgery Involving One-Lung Ventilation
by Sara Larsen & Jimmy Højberg Holm & Tove Nørgaard Sauer & Claus Andersen - 171-179 Buccal Midazolam Solution for the Management of Prolonged Acute Convulsive Seizures: A Cost Analysis
by Catherine Ludwig & Lauri Fisher - 181-190 Medical Costs of Patients with Type 2 Diabetes in a Single Payer System: A Classification and Regression Tree Analysis
by Paola Rucci & Vera Maria Avaldi & Claudio Travaglini & Cristina Ugolini & Elena Berti & Maria Luisa Moro & Maria Pia Fantini